We further discussed the phase 1 to 3 clinical trials reporting the efficacy, safety, and tolerability pertaining to the use of neratinib in the treatment of BC, with a focus on the clinical use of neratinib in the management of HER2-positive BC with CNS metastasis. This evidence concerns the gene ERBB2 and breast cancer.